SCHEMBL13656198

SCHEMBL13656198

CC(C)N1CCCc2cc(C(C)(C)C)ccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
NOTUM Q6P988 2/20 0.38
NLRP3 Q96P20 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 1/20 0.35
RORC P51449 5/20 0.34
NR1H3 Q13133 2/20 0.34
NR1I2 O75469 1/20 0.33
NR1H2 P55055 1/20 0.33
NR3C1 P04150 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13683390 0.90 CYP3A4 (0.45) TP53CYP3A4CYP2C9NOTUMLMNA
SCHEMBL22843391 0.86 NOTUM (0.50) TP53HDAC1HDAC6NOTUMLMNA
SCHEMBL24721757 0.80 NLRP3 (0.40) TP53CYP3A4CYP2C9HDAC1HDAC6
SCHEMBL762346 0.79 ALDH1A1 (0.55) TP53CYP3A4CYP2C9NOTUMNLRP3
SCHEMBL13112859 0.79 TP53 (0.47) TP53CYP3A4CYP2C9NOTUMNLRP3
SCHEMBL12356968 0.79 ALDH1A1 (0.55) TP53NOTUMPOLBALDH1A1MEN1
SCHEMBL22816781 0.78 PDK1 (0.43) CYP3A4HDAC1HDAC6NOTUMLMNA
SCHEMBL12382109 0.78 NOTUM (0.46) HDAC1HDAC6NOTUMALDH1A1MEN1
SCHEMBL21140749 0.78 CYP3A4 (0.38) TP53CYP3A4CYP2C9NOTUMNLRP3
SCHEMBL17169813 0.78 HDAC1 (0.56) HDAC1HDAC6NOTUMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180057458-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2018-03-01 US disclosed
US-20180057458-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2018-03-01 US disclosed
US-7605176-B2 β-ketoamide compounds with MCH antagonistic activity BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-20 US disclosed
US-7592373-B2 Amide compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-22 US disclosed
US-7592373-B2 Amide compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180057458-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX TP53 4651/4885CYP3A4 1301/4885CYP2C9 1116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.